Two researchers at
the Hebrew University (HU)
of Jerusalem have been honored with a prestigious award for their
study of the
connection between several inflammatory diseases, cancer and bacteria.
Two researchers at
the Hebrew University (HU)
of Jerusalem have been honored with a prestigious award for their study of the
connection between several inflammatory diseases, cancer and bacteria.
HTML clipboardTwo
plates which were coated with an antibiotic-resistant bacteria called
Klebsiella with a mutation called NDM 1 and then exposed to various
antibiotics are seen at the Health Protection Agency in north London March
9, 2011. The clear areas in the right half of the left-hand plate show
that the Klebsiella with NDM 1 was sensitive to the antibiotic tigecycline
(manufactured by Pfizer under the trade name Tygacil). For decades
scientists have managed to develop new medicines to stay at least one step
ahead of the ever-mutating enemy, bacteria. Now, though, we may be running
out of road. Methicillin-resistant Staphylococcus aureus, commonly known
as MRSA, alone is estimated to kill around 19,000 people every year in the
United States -- far more than HIV and AIDS -- and a similar number in
Europe, and other drug-resistant superbugs are spreading.(Xinhua/Reuters
Photo)
Medical faculty members, Dr. Eli Pilarsky and Prof. Sigal
Ben- Yehuda, won this year's Sir Zelman Cowen Universities Fund prize that
recognizes significant achievement in the field of medicine.
The prize committee noted the impressive contributions of
Pilarsky and Ben-Yehuda in understanding complex diseases like cancer and
antibiotic-resistant infections, and, in a first, decided to award the two
scientists this year.
Pilarsky told Xinhua that his research deals with the
connection between chronic inflammatory diseases like hepatitis, and the
development of cancer cells.
"The relevance of this discovery is that we were able to
establish the link between the molecules secreted with such inflammations and
the proliferation of cancer cells," Pilarsky explained, noting that "we
discovered that the inflammation favors the cancer cells' growth, and now we
are trying to find a way to manipulate these molecules to stop the cancer
cells from appearing. "
"The importance of these findings lies in the fact that 20
percent of the world's cancer cases are attributed to inflammation processes,"
Pilarsky pointed out.